TRO19622, developed by Hoffmann-La Roche, is positioned as an add-on therapy to the existing ALS treatment, Riluzole. The ALS market is characterized by limited treatment options, with Riluzole being the only approved drug that has shown a modest effect on survival. The success of TRO19622 could provide a significant competitive advantage, addressing a critical unmet need in ALS therapy. The trial's completion and subsequent results may enhance Roche's portfolio in neurology, potentially leading to market exclusivity if the product demonstrates efficacy and safety. Given the high incidence of ALS and the increasing focus on neurodegenerative diseases, the commercial prospects appear promising, contingent upon positive trial outcomes.